Literature DB >> 25358267

Grading of neuroendocrine neoplasms: mitoses and Ki-67 are both essential.

Marie-Louise F van Velthuysen1, Emma J Groen, Vincent van der Noort, Arjen van de Pol, Margot E T Tesselaar, Catharina M Korse.   

Abstract

BACKGROUND: The current WHO classification for neuroendocrine neoplasms (NEN) of the gastrointestinal tract requires Ki-67 and mitotic index for grading. However, both indexes might be conflicting as far as grade is concerned. In this study, we investigate which of the two indexes is most informative to predict survival.
METHODS: We assessed 362 patients with NEN of gastrointestinal (n = 148), pancreatic (n = 29), lung (n = 77), unknown primary site (n = 102) and of miscellaneous (n = 6) origin. Follow-up and proliferative indexes were recorded.
RESULTS: Survival was clearly correlated with both proliferative indexes (p < 0.001). One hundred and nineteen samples (34%) showed discordance in grading between the Ki-67 and the mitotic index, of which 74 (62%) were biopsies and 45 (38%) resection specimens (p = 0.001). In 86% of these cases, survival matched with the highest proliferative index, which was the Ki-67 index in 87% of these cases. Seventeen cases had a mitotic index of 2 (threshold grade 2) and a Ki-67 index of <3% (grade 1). For these cases, survival curve matched that of patients with concordant indexes of grade 1.
CONCLUSION: Grading NEN using two proliferative markers results in discordance between these indexes in one third of cases, more often in biopsy material than in resection specimens. If results are discordant, survival is for the most part associated with the grade of the highest index, for the most part Ki-67. Thus, grading with two proliferative indexes is useful as it highlights cases where one of these indexes may be incongruent.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25358267     DOI: 10.1159/000369275

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  17 in total

Review 1.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

Review 2.  Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.

Authors:  Romain Coriat; Thomas Walter; Benoît Terris; Anne Couvelard; Philippe Ruszniewski
Journal:  Oncologist       Date:  2016-07-08

3.  Efficient Prediction of Ki-67 Proliferation Index in Meningiomas on MRI: From Traditional Radiological Findings to a Machine Learning Approach.

Authors:  Yanjie Zhao; Jianfeng Xu; Boran Chen; Le Cao; Chaoyue Chen
Journal:  Cancers (Basel)       Date:  2022-07-26       Impact factor: 6.575

Review 4.  Classification of pulmonary neuroendocrine tumors: new insights.

Authors:  Giuseppe Pelosi; Angelica Sonzogni; Sergio Harari; Adriana Albini; Enrica Bresaola; Caterina Marchiò; Federica Massa; Luisella Righi; Gaia Gatti; Nikolaos Papanikolaou; Namrata Vijayvergia; Fiorella Calabrese; Mauro Papotti
Journal:  Transl Lung Cancer Res       Date:  2017-10

Review 5.  Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Andrew M Bellizzi
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495

6.  Diagnosis and prognostic significance of extramural venous invasion in neuroendocrine tumors of the small intestine.

Authors:  Qingqing Liu; Alexandros D Polydorides
Journal:  Mod Pathol       Date:  2020-06-08       Impact factor: 7.842

7.  Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask.

Authors:  Manuela Albertelli; Federica Grillo; Fabio Lo Calzo; Giulia Puliani; Carmen Rainone; Annamaria Anita Livia Colao; Antongiulio Faggiano
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-23       Impact factor: 5.555

8.  A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy.

Authors:  Jasminka Hasic Telalovic; Serena Pillozzi; Rachele Fabbri; Alice Laffi; Daniele Lavacchi; Virginia Rossi; Lorenzo Dreoni; Francesca Spada; Nicola Fazio; Amedeo Amedei; Ernesto Iadanza; Lorenzo Antonuzzo
Journal:  Diagnostics (Basel)       Date:  2021-04-28

Review 9.  What is New in the 2019 World Health Organization (WHO) Classification of Tumors of the Digestive System: Review of Selected Updates on Neuroendocrine Neoplasms, Appendiceal Tumors, and Molecular Testing.

Authors:  Naziheh Assarzadegan; Elizabeth Montgomery
Journal:  Arch Pathol Lab Med       Date:  2021-06-01       Impact factor: 5.686

10.  Ki67--An unsuitable marker of gastric cancer prognosis unmasks intratumoral heterogeneity.

Authors:  Christine Böger; Hans-Michael Behrens; Christoph Röcken
Journal:  J Surg Oncol       Date:  2015-12-28       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.